Clinical trials: Medication Therapy Management
Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis (MS)
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Trial name
- TOP MS (NCT00819000)
- Testing
- Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
- Where
- 3 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Teva Neuroscience, Inc.
Grade I or II Essential Hypertension
Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.
The objective of this study is to compare the efficacy and safety of combined administration of TAK-536CCB (Fix-dose combination of Azilsartan and Amlodipine) and Hydrochlorothiazide (HCTZ) with those of TAK-536CCB in patients…
- Trial name
- NCT02072330
- Testing
- TAK-536CCB, TAK-536CCB + Hydrochlorothiazide, Hydrochlorothiazide
- Where
- 13 sites in Japan
- Volunteers
- 353 people
- Sponsor
- Takeda
Hereditary Angioedema (HAE)
A Survey of Lanadelumab in Participants With Hereditary Angioedema
This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics…
- Trial name
- NCT05397431
- Testing
- Lanadelumab
- Where
- Japan
- Volunteers
- 155 people
- Sponsor
- Takeda
Autistic Disorder
Extended Management and Measurement of Autism
This open-label research study will continue to monitor the safety of fluoxetine in children after their completion of a previous double-blind placebo controlled clinical study, with fluoxetine.
- Trial name
- EMMA (NCT00787111)
- Testing
- Fluoxetine (prozac)
- Where
- 13 sites in United States
- Volunteers
- 128 people
- Sponsor
- Neuropharm
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Obesity, Weight Change Trajectory
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both…
- Conditions
- Obesity, Weight Change Trajectory, Weight Change, Body
- Trial name
- REMAIN-1 (NCT06484114)
- Testing
- Revita Duodenal Mucosal Resurfacing (DMR)
- Where
- 32 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Fractyl Health Inc.
Dengue Fever
Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years
The purpose of the study is to demonstrate the non-inferiority (NI) of the immune response to 2 doses of 9vHPV vaccine, 1 co-administered with TDV, compared with 2 doses of 9vHPV vaccine administered alone.
- Trial name
- NCT04313244
- Testing
- 9vHPV Vaccine, Dengue Tetravalent Vaccine (TDV)
- Where
- 4 sites in Thailand
- Volunteers
- 614 people, healthy volunteers welcome
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
HIV Infections
The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
To evaluate the safety and tolerance of adefovir dipivoxil and indinavir administered orally in combination with zidovudine, lamivudine, or stavudine in HIV-infected patients with CD4 cell counts >= 100 cells/mm3 and an HIV-1 RNA…
- Trial name
- NCT00002379
- Testing
- Indinavir sulfate, Levocarnitine, Adefovir dipivoxil
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
Obesity, Overweight
A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects
The purpose of this study is to determine whether 2 doses of the combination of naltrexone SR and bupropion SR are safe and effective in the treatment of obesity.
- Trial name
- NCT00532779
- Testing
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Ancillary therapy
- Where
- 34 sites in United States
- Volunteers
- 1,742 people
- Sponsor
- Orexigen Therapeutics, Inc
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy
Study to Assess the Effects of Daily Administration of Pioglitazone on Brain Hemodynamics in Healthy Elderly Participants
The purpose of this study is to assess the effects of pioglitazone, once daily (QD), on brain hemodynamics in healthy elderly participants.
- Trial name
- NCT01456117
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Takeda
Opioid Withdrawal (Disorder), Opioid Use Disorder
A Pharmacokinetic, Safety, and Tolerability Study of LUCEMYRA in the Treatment of Opioid Withdrawal Management in Adolescent Subjects
The goal of this clinical study is to evaluate the pharmacokinetic (PK), safety, and tolerability of LUCEMYRA in adolescents age ≥12 to <18 years old abruptly discontinuing opioid use.
- Trial name
- NCT06711640
- Testing
- LUCEMYRA (lofexidine) tablets
- Where
- United States
- Sponsor
- USWM, LLC (dba US WorldMeds)
Healthy Volunteers
Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule
The purpose of this study is to assess the effect of antacid administration, and its timing, on the bioavailability of a single dose of febuxostat extended-release (XR) 80 mg.
- Trial name
- NCT02382640
- Testing
- Febuxostat XR, Maalox Advance Regular Strength liquid
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Hypercholesterolemia, Familial Hypercholesterolemia
A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245)
This study is a non-interventional (observational) study in Japan to confirm the safety and efficacy of Zetia when administered alone or in combination with other lipid-lowering drugs in daily medical practice throughout a…
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia, Homozygous Sitosterolemia
- Trial name
- NCT00705211
- Testing
- Ezetimibe, Ezetimibe + other lipid-lowering medication(s)
- Volunteers
- 1,794 people
- Sponsor
- Organon and Co
Pharmacogenomics, Medication Therapy Management
A Pharmacist Implemented Pharmacogenomics Service in the Program of All-inclusive Care for the Elderly
The aim of this study is to evaluate and describe the feasibility of implementing a pharmacist-led pharmacogenomics service for the Program of All-inclusive Care for the Elderly (PACE), a community-based practice setting.
- Trial name
- PACE (NCT03257605)
- Volunteers
- 296 people
- Sponsor
- Tabula Rasa HealthCare
HIV Infections
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
The purpose of this study is to see how safe a new protease inhibitor (PI) is and how well it fights HIV infection. A PI is a drug that stops HIV from using healthy cells to make more virus.
- Trial name
- NCT00004583
- Testing
- Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine
- Where
- 83 sites in United States, Australia and 12 more
- Volunteers
- 660 people
- Sponsor
- Abbott
Erosive Esophagitis
Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis
The purpose of the study is to demonstrate the efficacy of vonoprazan (TAK-438) versus lansoprazole in the treatment of erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.
- Trial name
- NCT02388724
- Testing
- Vonoprazan, Lansoprazole
- Where
- 64 sites in China, Malaysia and 2 more
- Volunteers
- 481 people
- Sponsor
- Takeda
Dermatitis, Atopic, Eczema, Atopic
Long-term Safety of Protopic in Atopic Eczema
Patients who have participated in previous studies with Tacrolimus ointment for atopic eczema are entitled to enter this four-year follow study to investigate the safety of treatment with Tacrolimus ointment 0.1%
- Trial name
- NCT00560378
- Testing
- Tacrolimus ointment 0.1%
- Where
- 41 sites in Belgium, Denmark and 10 more
- Volunteers
- 789 people
- Sponsor
- Astellas Pharma Inc
Epilepsy Intractable
A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.
- Trial name
- NCT02987114
- Testing
- PLT101
- Where
- Israel
- Volunteers
- 16 people
- Sponsor
- PhytoTech Therapeutics, Ltd.